Continue to Site »
Site will load in 15 seconds

Canadian Cannabis Company, The Flowr Corporation, To Begin Trading on the TSX Venture Exchange

The licensed producer is focused on growing premium cannabis and is rapidly scaling operations to meet medicinal and adult-use demand.


MARKHAM, Ontario, September 26, 2018 – PRESS RELEASE – The Flowr Corporation has announced that it expects its shares to be available for trading on the TSX Venture Exchangeunder the symbol FLWR at market open on Sept. 26, 2018. This follows the recent completion by Flowr of both an oversubscribed $C36 million capital raise and reverse takeover of a capital pool company previously listed on the Exchange.

“This is an exciting day and important step toward our goal of becoming one of Canada’s top licensed producers,” said Vinay Tolia, Flowr’s CEO. “With the transaction behind us, we can increase our focus on executing our business plan."

Flowr Business Overview

Flowr is an emerging Canadian cannabis company founded by MedReleaf co-founder Tom Flow and a team of industry pioneers, start-up executives and industry scientists. Flowr’s purpose-built cultivation facilities are designed to generate high crop yields and produce premium and ultra-premium cannabis products. Company management believes that its focus on premium products and its highly efficient cultivation facilities create the potential for significant growth.

Cultivation

Flowr’s flagship 85,000-square-foot cultivation facility in Kelowna, British Columbia, employs proprietary cultivation systems and is engineered to meet pharmaceutical quality production standards allowing the company to grow premium cannabis flower. Flowr carefully harvests, hand trims and craft cures its products. Together, these exacting protocols allow the company to consistently provide an outstanding cannabis experience to its customers

The Kelowna facility is presently approximately 20 percent operational with the remaining 80 percent slated to come online in early 2019. It is expected to produce upwards of 12,000 kilograms of cannabis flower annually once fully operational. The company expects to add more cultivation capacity and take steps designed to further increase crop yields in the near future.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Markham, Ontario, cultivation facility. MedReleaf has long been known as one of Canada’s most efficient and profitable LPs and was acquired by Aurora Cannabis Inc. for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producers licences under Health Canada’s ACMPR.

Research & Development

In March 2018, Flowr and the Hawthorne Gardening Company, a subsidiary of The Scotts Miracle-Gro Company–lawn and garden products compay–announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities. This makes Flowr one of only three Canadian cannabis companies with a business partnership with a publicly traded U.S. company along with Canopy and Hexo (formerly Hydropothecary).

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in 2019. Management expects Flowr’s R&D program to help the company maintain its competitive advantage in cultivation and keep it on the cutting edge of cannabis innovation.

Products and Sales

Flowr obtained its Health Canada Sales License earlier this year and has agreements with three provinces to supply premium cannabis for sale in the adult recreational use market that is expected to open Oct. 17, 2018. The company recently announced it had started sales to the medical market via its website. 

Flowr will offer two different brands for the medicinal and adult-use markets:

  • FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives.  A dedicated, bilingual team of client service nurses will provide patients with personalized support while Flowr’s R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process–from genetic selection to harvest, trimming and curing techniques. Flowr also offers convenient and discreet online consultations with healthcare professionals to facilitate medical documentation.
  • Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Cultivated in the world famous Okanagan Valley of British Columbia, hand trimmed and craft cured, Flowr’s premium products will deliver unparalleled experiences.

Growth Opportunities

Flowr’s management believes the company is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company is pursuing a growth strategy focused on increasing yields and producing premium-quality, premium-priced cannabis at scale.

The company also intends to pursue a variety of other growth opportunities. These include potential business partnerships with well-known brands seeking to enter the cannabis market, exploring export opportunities, potentially entering the market to provide cannabis in additional form factors such as ingestibles, beverages and vape products when those form factors become legal in Canada, and evaluating opportunities in genetics and plant and seed sales.

Page 1 of 183
Next Page